• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Multiple sclerosis therapeutic strategies: Use second-line agents as first-line agents when time is of the essence.多发性硬化症治疗策略：在时间紧迫时，将二线药物用作一线药物。
Neurol Clin Pract. 2011 Dec;1(1):66-68. doi: 10.1212/CPJ.0b013e31823cc2c2.
2
How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP).多发性硬化症的疾病修饰治疗转换：法国多发性硬化症学会（SFSEP）指南。
Mult Scler Relat Disord. 2021 Aug;53:103076. doi: 10.1016/j.msard.2021.103076. Epub 2021 Jun 10.
3
Back to the future for multiple sclerosis therapy: focus on current and emerging disease-modifying therapeutic strategies.多发性硬化症治疗的回顾与展望：聚焦现有及新兴的疾病修正治疗策略。
Immunotherapy. 2009 May;1(3):403-23. doi: 10.2217/imt.09.7.
4
Discontinuation of second- versus first-line disease-modifying treatment in middle-aged patients with multiple sclerosis.中年多发性硬化症患者二线与一线疾病修饰治疗的停药情况
J Neurol. 2023 Jan;270(1):413-422. doi: 10.1007/s00415-022-11341-2. Epub 2022 Sep 16.
5
How much progress has there been in the second-line treatment of multiple sclerosis: A 2017 update.多发性硬化二线治疗的进展有多少：2017 年更新。
Rev Neurol (Paris). 2018 Jun;174(6):429-440. doi: 10.1016/j.neurol.2018.01.369. Epub 2018 May 17.
6
Therapeutic strategies of urinary disorders in MS. Practice and algorithms.多发性硬化症泌尿系统疾病的治疗策略。实践与算法。
Ann Phys Rehabil Med. 2014 Jul;57(5):297-301. doi: 10.1016/j.rehab.2014.05.003. Epub 2014 Jun 4.
7
Expert opinion: Criteria for second-line treatment failure in patients with multiple sclerosis.专家观点：多发性硬化症患者二线治疗失败的标准。
Mult Scler Relat Disord. 2019 Nov;36:101406. doi: 10.1016/j.msard.2019.101406. Epub 2019 Sep 19.
8
Update on treatments in multiple sclerosis.多发性硬化症治疗进展
Presse Med. 2015 Apr;44(4 Pt 2):e137-51. doi: 10.1016/j.lpm.2015.02.008. Epub 2015 Mar 23.
9
Disease modifying therapies and disease activity during pregnancy and postpartum in a contemporary cohort of relapsing Multiple Sclerosis patients.在当代复发型多发性硬化症患者的队列中，疾病修饰疗法和妊娠及产后的疾病活动情况。
Mult Scler Relat Disord. 2022 Dec;68:104122. doi: 10.1016/j.msard.2022.104122. Epub 2022 Aug 15.
10
Highly active disease and access to disease-modifying treatments in patients with relapsing-remitting multiple sclerosis in Poland.波兰复发缓解型多发性硬化症患者的高活性疾病和疾病修正治疗的可及性。
Neurol Neurochir Pol. 2022;56(3):256-260. doi: 10.5603/PJNNS.a2022.0047. Epub 2022 Jun 29.

引用本文的文献

1
Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis.在复发型多发性硬化症的ULTIMATE 3期研究中，与特立氟胺相比，乌布利昔单抗治疗无疾病活动证据的改善情况。
Front Neurol. 2024 Oct 24;15:1473284. doi: 10.3389/fneur.2024.1473284. eCollection 2024.
2
Updates and advances in multiple sclerosis neurotherapeutics.多发性硬化症神经治疗学的最新进展。
Neurodegener Dis Manag. 2023 Feb;13(1):47-70. doi: 10.2217/nmt-2021-0058. Epub 2022 Oct 31.
3
Evolution of Cortical and White Matter Lesion Load in Early-Stage Multiple Sclerosis: Correlation With Neuroaxonal Damage and Clinical Changes.早期多发性硬化症中皮质和白质病变负荷的演变：与神经轴突损伤及临床变化的相关性
Front Neurol. 2020 Sep 4;11:973. doi: 10.3389/fneur.2020.00973. eCollection 2020.
4
Pregnancy and multiple sclerosis: Risk of unplanned pregnancy and drug exposure in utero.妊娠与多发性硬化症：意外妊娠及子宫内药物暴露风险。
Mult Scler J Exp Transl Clin. 2019 Dec 12;5(4):2055217319891744. doi: 10.1177/2055217319891744. eCollection 2019 Oct-Dec.
5
Therapeutic Targets for Multiple Sclerosis: Current Treatment Goals and Future Directions.多发性硬化症的治疗靶点：当前的治疗目标和未来方向。
Neurotherapeutics. 2017 Oct;14(4):952-960. doi: 10.1007/s13311-017-0548-5.
6
Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis.延缓多发性硬化症患者残疾进展的药理学方法
Drugs. 2015 Jun;75(9):947-77. doi: 10.1007/s40265-015-0411-0.

本文引用的文献

1
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.在复发缓解型多发性硬化症中比较芬戈莫德与干扰素 β-1a：TRANSFORMS 研究的随机扩展。
Lancet Neurol. 2011 Jun;10(6):520-9. doi: 10.1016/S1474-4422(11)70099-0. Epub 2011 May 13.
2
Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.CLARITY 研究中用克拉屈滨片治疗的复发缓解型多发性硬化患者的持续疾病活动状态无进展：一项事后和亚组分析。
Lancet Neurol. 2011 Apr;10(4):329-37. doi: 10.1016/S1474-4422(11)70023-0.
3
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.口服芬戈莫德或肌肉注射干扰素治疗复发型多发性硬化。
N Engl J Med. 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20.
4
'Time is brain' also in multiple sclerosis.“时间就是大脑”在多发性硬化症中同样适用。
Mult Scler. 2009 Oct;15(10):1133-4. doi: 10.1177/1352458509345920. Epub 2009 Oct 6.
5
Pathological heterogeneity of idiopathic central nervous system inflammatory demyelinating disorders.特发性中枢神经系统炎性脱髓鞘疾病的病理异质性
Curr Top Microbiol Immunol. 2008;318:19-43. doi: 10.1007/978-3-540-73677-6_2.
6
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.那他珠单抗联合干扰素β-1a治疗复发型多发性硬化症。
N Engl J Med. 2006 Mar 2;354(9):911-23. doi: 10.1056/NEJMoa044396.
7
Axonal transection in the lesions of multiple sclerosis.多发性硬化症病变中的轴突横断
N Engl J Med. 1998 Jan 29;338(5):278-85. doi: 10.1056/NEJM199801293380502.

Multiple sclerosis therapeutic strategies: Use second-line agents as first-line agents when time is of the essence.

作者信息

Freedman Mark S

机构信息

Ottawa Hospital, Ottawa, Canada.

出版信息

Neurol Clin Pract. 2011 Dec;1(1):66-68. doi: 10.1212/CPJ.0b013e31823cc2c2.

DOI:10.1212/CPJ.0b013e31823cc2c2
PMID:29443288
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5766179/
Abstract
摘要